Skip to main content
SpringerLink
Log in

The feasibility of contrast-enhanced spectral mammography immediately after contrast-enhanced CT

  • Published:
Radiological Physics and Technology Aims and scope Submit manuscript

Abstract

Contrast-enhanced spectral mammography (CESM) is a digital mammography method that requires an intravenous injection of iodinated contrast material to detect hypervascular lesions. In patients undergoing evaluation for metastases before breast tumor surgery, a contrast material must be injected for computed tomography (CT) and CESM studies. The purpose of our study was to investigate the feasibility of performing CESM immediately after contrast-enhanced CT, without injecting additional contrast material. We enrolled 77 women with 88 breast carcinomas. Immediately after contrast-enhanced CT, we performed CESM without injecting additional contrast material. The patients were divided into two groups based on the length of the interval between contrast material injection and the start of mammography. In group A (n = 51), it was less, and in group B (n = 26) it was more than 7 min. We measured the tumor gland contrast of each tumor on the CESM images and recorded the tumor opacification on a 4-point visual scale. The mean interval between the start of contrast material injection for CT and the acquisition of mammograms in groups A and B was 5.41 and 10.40 min, respectively. All lesions were detectable on the CESM images. There was no significant difference in the visual evaluation between the two groups (p = 0.21). CESM immediately after contrast-enhanced CT without the injection of additional contrast material is feasible and cost-effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Daniaux M, De Zordo T, Santner W, Amort B, Koppelstatter F, Jaschke W, et al. Dual-energy contrast-enhanced spectral mammography (CESM). Arch Gynecol Obstet. 2015;292(4):739–47. https://doi.org/10.1007/s00404-015-3693-2.

    Article  PubMed  Google Scholar 

  2. Blum KS, Rubbert C, Mathys B, Antoch G, Mohrmann S, Obenauer S. Use of contrast-enhanced spectral mammography for intramammary cancer staging: preliminary results. Acad Radiol. 2014;21(11):1363–9. https://doi.org/10.1016/j.acra.2014.06.012.

    Article  PubMed  Google Scholar 

  3. Badr S, Laurent N, Regis C, Boulanger L, Lemaille S, Poncelet E. Dual-energy contrast-enhanced digital mammography in routine clinical practice in 2013. Diagn Interv Imaging. 2014;95(3):245–58. https://doi.org/10.1016/j.diii.2013.10.002.

    Article  CAS  PubMed  Google Scholar 

  4. Lee-Felker SA, Tekchandani L, Thomas M, Gupta E, Andrews-Tang D, Roth A, et al. Newly diagnosed breast cancer: comparison of contrast-enhanced spectral mammography and breast MR imaging in the evaluation of extent of disease. Radiology. 2017;285(2):389–400. https://doi.org/10.1148/radiol.2017161592.

    Article  PubMed  Google Scholar 

  5. Pellerin O, Delorme L, Bellmann L, Sapoval M. Clinical presentation and percutaneous endovascular management of acute left subclavian artery thrombosis: report of two cases. Diagn Interv Imaging. 2014;95(1):95–9. https://doi.org/10.1016/j.diii.2013.07.005.

    Article  CAS  PubMed  Google Scholar 

  6. Uhlig J, Fischer U, von Fintel E, Stahnke V, Perske C, Lotz J, et al. Contrast enhancement on cone-beam breast-CT for discrimination of breast cancer immunohistochemical subtypes. Transl Oncol. 2017;10(6):904–10. https://doi.org/10.1016/j.tranon.2017.08.010.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Luczynska E, Niemiec J, Hendrick E, Heinze S, Jaszczynski J, Jakubowicz J, et al. Degree of enhancement on contrast enhanced spectral mammography (CESM) and lesion type on mammography (MG): comparison based on histological results. Med Sci Monit Int Med J Exp Clin Res. 2016;22:3886–933.

    Google Scholar 

  8. Bhimani C, Matta D, Roth RG, Liao L, Tinney E, Brill K, et al. Contrast-enhanced spectral mammography: technique, indications, and clinical applications. Acad Radiol. 2017;24(1):84–8. https://doi.org/10.1016/j.acra.2016.08.019.

    Article  PubMed  Google Scholar 

  9. Lobbes MB, Lalji U, Houwers J, Nijssen EC, Nelemans PJ, van Roozendaal L, et al. Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. Eur Radiol. 2014;24(7):1668–766. https://doi.org/10.1016/j.crad.2013.04.009.

    Article  PubMed  Google Scholar 

  10. Dromain C, Balleyguier C, Muller S, Mathieu MC, Rochard F, Opolon P, et al. Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography. AJR Am J Roentgenol. 2006;187(5):W528–37. https://doi.org/10.2214/AJR.05.1944.

    Article  PubMed  Google Scholar 

  11. Lobbes MB, Smidt ML, Houwers J, Tjan-Heijnen VC, Wildberger JE. Contrast enhanced mammography: techniques, current results, and potential indications. Clin Radiol. 2013;68(9):935–44. https://doi.org/10.1016/j.crad.2013.04.009.

    Article  CAS  PubMed  Google Scholar 

  12. Lewin JM, Isaacs PK, Vance V, Larke FJ. Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology. 2003;229(1):261–8. https://doi.org/10.1148/radiol.2291021276.

    Article  PubMed  Google Scholar 

  13. Dromain C, Thibault F, Muller S, Rimareix F, Delaloge S, Tardivon A, et al. Dual-energy contrast-enhanced digital mammography: initial clinical results. Eur Radiol. 2011;21(3):565–74. https://doi.org/10.1007/s00330-010-1944-y.

    Article  PubMed  Google Scholar 

  14. Shiraishi A, Kurosaki Y, Maehara T, Suzuki M, Kurosumi M. Extension of ductal carcinoma in situ: histopathological association with MR imaging and mammography. Magn Reson Med Sci. 2003;2(4):159–63.

    Article  PubMed  Google Scholar 

  15. Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49(6):658–67. https://doi.org/10.1080/02841850802050762.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan

    Nobuko Okada, Mai Sugai & Izumi Okita

  2. Department of Diagnostic Radiology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

    Fuminari Tatsugami & Kazuo Awai

  3. Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan

    Mitsuya Ito & Shoichiro Ohtani

  4. Department of Pathology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan

    Kouichi Ichimura

  5. Department of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan

    Masaki Urashima

Authors
  1. Nobuko Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fuminari Tatsugami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mai Sugai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Izumi Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuya Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoichiro Ohtani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kouichi Ichimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaki Urashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuo Awai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuko Okada.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All the procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okada, N., Tatsugami, F., Sugai, M. et al. The feasibility of contrast-enhanced spectral mammography immediately after contrast-enhanced CT. Radiol Phys Technol 12, 277–282 (2019). https://doi.org/10.1007/s12194-019-00518-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12194-019-00518-6

Keywords

Search

Navigation